Inhibition of poxvirus gene expression and genome replication by bisbenzimide derivatives

Journal of Virology

Volumn 91, Issue 18, 2017, Pages

  Yakimovich, Artur ^a,c   Huttunen, Moona ^c   Zehnder, Benno ^b   Coulter, Lesley J ^d   Gould, Victoria ^c   Schneider, Christoph ^b   Kopf, Manfred ^b   McInnes, Colin J ^d   Greber, Urs F ^a   Mercer, Jason ^b,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MOREDUN RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Antiviral agents; DNA replication; Poxvirus; Vaccinia virus; Viral transcription

Indexed keywords

ANTIVIRUS AGENT; FLUORESCENT DYE; PIBENZIMOL;

ANIMAL; CELL LINE; DNA REPLICATION; DRUG EFFECTS; GENETIC TRANSCRIPTION; HUMAN; PHYSIOLOGY; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BISBENZIMIDAZOLE; CELL LINE; DNA REPLICATION; FLUORESCENT DYES; HUMANS; TRANSCRIPTION, GENETIC; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 85028341435     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00838-17     Document Type: Article

References (73)

1. Lederberg J. 2000. Infectious history. Science 288:287-293. https://doi.org/10.1126/science.288.5464.287
2. Greber UF, Bartenschlager R. 2017. Editorial: an expanded view of viruses. FEMS Microbiol Rev 41:1-4. https://doi.org/10.1093/femsre/ fuw044
3. Koonin EV, Dolja VV, Krupovic M. 2015. Origins and evolution of viruses of eukaryotes: the ultimate modularity. Virology 479:2-25. https://doi.org/10.1016/j.virol.2015.02.039
4. Prasad V, Suomalainen M, Hemmi S, Greber UF. 2017. The cell cycledependent kinase Cdk9 is a postexposure drug target against human adenoviruses. ACS Infect Dis 3:398-405. https://doi.org/10.1021/ acsinfecdis.7b00009
5. Santos-Fernandes E, Beltrame CO, Byrd CM, Cardwell KB, Schnellrath LC, Medaglia ML, Hruby DE, Jordan R, Damaso CR. 2013. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246. Antiviral Res 97:301-311. https://doi.org/10.1016/j.antiviral.2012.11.010
6. Moussatche N, Damaso CR, McFadden G. 2008. When good vaccines go wild: feral orthopoxvirus in developing countries and beyond. J Infect Dev Ctries 2:156-173. https://doi.org/10.3855/jidc.258
7. Kurth A, Wibbelt G, Gerber HP, Petschaelis A, Pauli G, Nitsche A. 2008. Rat-to-elephant-to-human transmission of cowpox virus. Emerg Infect Dis 14:670-671. https://doi.org/10.3201/eid1404.070817
8. Vogel S, Sardy M, Glos K, Korting HC, Ruzicka T, Wollenberg A. 2012. The Munich outbreak of cutaneous cowpox infection: transmission by infected pet rats. Acta Derm Venereol 92:126-131. https://doi.org/10.2340/00015555-1227
9. Duraffour S, Mertens B, Meyer H, van den Oord JJ, Mitera T, Matthys P, Snoeck R, Andrei G. 2013. Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals. PLoS One 8:e55808. https://doi.org/10.1371/journal.pone.0055808
10. Di Giulio DB, Eckburg PB. 2004. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 4:15-25. https://doi.org/10.1016/S1473-3099(03)00856-9
11. Hutson CL, Lee KN, Abel J, Carroll DS, Montgomery JM, Olson VA, Li Y, Davidson W, Hughes C, Dillon M, Spurlock P, Kazmierczak JJ, Austin C, Miser L, Sorhage FE, Howell J, Davis JP, Reynolds MG, Braden Z, Karem KL, Damon IK, Regnery RL. 2007. Monkeypox zoonotic associations: insights from laboratory evaluation of animals associated with the multistate US outbreak. Am J Trop Med Hyg 76:757-768
12. Shchelkunov SN. 2013. An increasing danger of zoonotic orthopoxvirus infections. PLoS Pathog 9:e1003756. https://doi.org/10.1371/journal.ppat.1003756
13. Kemper AR, Davis MM, Freed GL. 2002. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 5:84-90
14. Belongia EA, Naleway AL. 2003. Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res 1:87-92. https://doi.org/10.3121/cmr.1.2.87
15. De Clercq E. 2002. Cidofovir in the treatment of poxvirus infections. Antiviral Res 55:1-13. https://doi.org/10.1016/S0166-3542(02)00008-6
16. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 79:13139-13149. https://doi.org/10.1128/JVI.79.20.13139-13149.2005
17. Blasco R, Moss B. 1991. Extracellular vaccinia virus formation and cellto-cell virus transmission are prevented by deletion of the gene encoding the 37, 000-dalton outer envelope protein. J Virol 65:5910-5920
18. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, Jordan R, Marbury T, Ruckle J, Mee-Lee D, Ross E, Lichtenstein I, Pickens M, Corrado M, Clarke JM, Frimm AM, Hruby DE. 2012. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother 56:4900-4905. https://doi.org/10.1128/ AAC.00904-12
19. Becker MN, Obraztsova M, Kern ER, Quenelle DC, Keith KA, Prichard MN, Luo M, Moyer RW. 2008. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol J 5:58. https://doi.org/10.1186/1743-422X-5-58
20. James SH, Price NB, Hartline CB, Lanier ER, Prichard MN. 2013. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother 57:3321-3325. https://doi.org/10.1128/AAC.00062-13
21. De Gascun CF, Carr MJ. 2013. Human polyomavirus reactivation: disease pathogenesis and treatment approaches. Clin Dev Immunol 2013: 373579. https://doi.org/10.1155/2013/373579
22. Magee WC, Hostetler KY, Evans DH. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49:3153-3162. https://doi.org/10.1128/AAC.49.8.3153-3162.2005
23. Bradbury J. 2002. Orally available cidofovir derivative active against smallpox. Lancet 359:1041. https://doi.org/10.1016/S0140-6736(02)08115-1
24. Morris K. 1998. Short course of AZT halves HIV-1 perinatal transmission. Lancet 351:651. https://doi.org/10.1016/S0140-6736(05)78436-1
25. Fornander LH, Wu L, Billeter M, Lincoln P, Norden B. 2013. Minor-groove binding drugs: where is the second Hoechst 33258 molecule? J Phys Chem B 117:5820-5830. https://doi.org/10.1021/jp400418w
26. Han F, Taulier N, Chalikian TV. 2005. Association of the minor groove binding drug Hoechst 33258 with d(CGCGAATTCGCG)2: volumetric, calorimetric, and spectroscopic characterizations. Biochemistry 44: 9785-9794. https://doi.org/10.1021/bi047374f
27. Smith PJ, Lacy M, Debenham PG, Watson JV. 1988. A mammalian cell mutant with enhanced capacity to dissociate a bis-benzimidazole dye-DNA complex. Carcinogenesis 9:485-490. https://doi.org/10.1093/ carcin/9.3.485
28. Comings D, Avelino E. 1975. Mechanisms of chromosome banding. Chromosoma 51:365-379. https://doi.org/10.1007/BF00326323
29. Latt SA, Stetten G. 1976. Spectral studies on 33258 Hoechst and related bisbenzimidazole dyes useful for fluorescent detection of deoxyribonucleic acid synthesis. J Histochem Cytochem 24:24-33. https://doi.org/10.1177/24.1.943439
30. Olive PL, Chaplin DJ, Durand RE. 1985. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer 52:739-746. https://doi.org/10.1038/bjc.1985.252
31. Wang X-J, Chu N-Y, Wang Q-H, Liu C, Jiang C-G, Wang X-Y, Ikejima T, Cheng M-S. 2012. Newly synthesized bis-benzimidazole derivatives exerting anti-tumor activity through induction of apoptosis and autophagy. Bioorg Med Chem Lett 22:6297-6300. https://doi.org/10.1016/ j.bmcl.2012.06.102
32. Baraldi PG, Bovero A, Fruttarolo F, Preti D, Tabrizi MA, Pavani MG, Romagnoli R. 2004. DNA minor groove binders as potential antitumor and antimicrobial agents. Med Res Rev 24:475-528. https://doi.org/10.1002/med.20000
33. Chen AY, Yu C, Bodley A, Peng LF, Liu LF. 1993. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 53:1332-1337
34. Soderlind KJ, Gorodetsky B, Singh AK, Bachur NR, Miller GG, Lown JW. 1999. Bis-benzimidazole anticancer agents: targeting human tumour helicases. Anticancer Drug Des 14:19-36
35. Woynarowski JM, McHugh M, Sigmund RD, Beerman TA. 1989. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4=, 6-diamidine-2-phenylindole. Mol Pharmacol 35:177-182
36. Latt SA, Stetten G, Juergens LA, Willard HF, Scher CD. 1975. Recent developments in the detection of deoxyribonucleic acid synthesis by 33258 Hoechst fluorescence. J Histochem Cytochem 23:493-505. https:// doi.org/10.1177/23.7.1095650
37. Downs TR, Wilfinger WW. 1983. Fluorometric quantification of DNA in cells and tissue. Anal Biochem 131:538-547. https://doi.org/10.1016/ 0003-2697(83)90212-9
38. Goracci L, Germani R, Savelli G, Bassani DM. 2005. Hoechst 33258 as a pH-sensitive probe to study the interaction of amine oxide surfactants with DNA. Chembiochem 6:197-203. https://doi.org/10.1002/cbic.200400196
39. Schabel FM, Jr. 1968. The antiviral activity of 9-β-D-arabinofu-ranosyladenine (ARA-A). Chemotherapy 13:321-338. https://doi.org/10.1159/000220567
40. Furth JJ, Cohen SS. 1968. Inhibition of mammalian DNA polymerase by the 5=-triphosphate of 1-beta-D-arabinofuranosylcytosine and the 5=-triphosphate of 9-beta-D-arabinofuranoxyladenine. Cancer Res 28: 2061-2067
41. Yakimovich A, Andriasyan V, Witte R, Wang IH, Prasad V, Suomalainen M, Greber UF. 2015. Plaque2.0-a high-throughput analysis framework to score virus-cell transmission and clonal cell expansion. PLoS One 10: e0138760. https://doi.org/10.1371/journal.pone.0138760
42. Kilcher S, Mercer J. 2015. DNA virus uncoating. Virology 479:578-590. https://doi.org/10.1016/j.virol.2015.01.024
43. Yamauchi Y, Greber UF. 2016. Principles of virus uncoating: cues and the snooker ball. Traffic 17:569-592. https://doi.org/10.1111/tra.12387
44. Mercer J, Snijder B, Sacher R, Burkard C, Bleck CK, Stahlberg H, Pelkmans L, Helenius A. 2012. RNAi screening reveals proteasome-and Cullin3-dependent stages in vaccinia virus infection. Cell Rep 2:1036-1047. https://doi.org/10.1016/j.celrep.2012.09.003
45. Welsch S, Doglio L, Schleich S, Krijnse Locker J. 2003. The vaccinia virus I3L gene product is localized to a complex endoplasmic reticulumassociated structure that contains the viral parental DNA. J Virol 77: 6014-6028. https://doi.org/10.1128/JVI.77.10.6014-6028.2003
46. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, Nichols R, Balser JP, Currie M, Monath TP. 2005. A novel, cell culturederived smallpox vaccine in vaccinia-naive adults. Vaccine 23: 3301-3309. https://doi.org/10.1016/j.vaccine.2005.01.079
47. Kilcher S, Schmidt FI, Schneider C, Kopf M, Helenius A, Mercer J. 2014. siRNA screen of early poxvirus genes identifies the AAA-ATPase D5 as the virus genome-uncoating factor. Cell Host Microbe 15:103-112. https://doi.org/10.1016/j.chom.2013.12.008
48. Wang I-H, Suomalainen M, Andriasyan V, Kilcher S, Mercer J, Neef A, Luedtke NW, Greber UF. 2013. Tracking viral genomes in host cells at single-molecule resolution. Cell Host Microbe 14:468-480. https://doi.org/10.1016/j.chom.2013.09.004
49. Senkevich TG, Koonin EV, Moss B. 2009. Predicted poxvirus FEN1-like nuclease required for homologous recombination, double-strand break repair and full-size genome formation. Proc Natl Acad Sci U S A 106: 17921-17926. https://doi.org/10.1073/pnas.0909529106
50. McInnes CJ, Wood AR, Nettleton PF, Gilray JA. 2001. Genomic comparison of an avirulent strain of Orf virus with that of a virulent wild type isolate reveals that the Orf virus G2L gene is non-essential for replication. Virus Genes 22:141-150. https://doi.org/10.1023/A:1008117127729
51. McInnes CJ, Wood AR, Thomas K, Sainsbury AW, Gurnell J, Dein FJ, Nettleton PF. 2006. Genomic characterization of a novel poxvirus contributing to the decline of the red squirrel (Sciurus vulgaris) in the UK. J Gen Virol 87:2115-2125. https://doi.org/10.1099/vir.0.81966-0
52. Yakimovich A, Gumpert H, Burckhardt CJ, Lütschg VA, Jurgeit A, Sbalzarini IF, Greber UF. 2012. Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model. J Virol 86:10123-10137. https://doi.org/10.1128/JVI.01102-12
53. Flatt JW, Greber UF. 12 May 2017. Viral mechanisms for docking and delivering at nuclear pore complexes. Semin Cell Dev Biol https://doi.org/10.1016/j.semcdb.2017.05.008
54. Moss B. 2007. Poxviridae: the viruses and their replication, p 2905-2946. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA
55. Cyrklaff M, Risco C, Fernandez JJ, Jimenez MV, Esteban M, Baumeister W, Carrascosa JL. 2005. Cryo-electron tomography of vaccinia virus. Proc Natl Acad Sci U S A 102:2772-2777. https://doi.org/10.1073/pnas.0409825102
56. Dales S. 1963. The uptake and development of vaccinia virus in strain L cells followed with labeled viral deoxyribonucleic acid. J Cell Biol 18: 51-72. https://doi.org/10.1083/jcb.18.1.51
57. Hollinshead M, Vanderplasschen A, Smith GL, Vaux DJ. 1999. Vaccinia virus intracellular mature virions contain only one lipid membrane. J Virol 73:1503-1517
58. Schmidt FI, Bleck CK, Reh L, Novy K, Wollscheid B, Helenius A, Stahlberg H, Mercer J. 2013. Vaccinia virus entry is followed by core activation and proteasome-mediated release of the immunomodulatory effector VH1 from lateral bodies. Cell Rep 4:464-476. https://doi.org/10.1016/j.celrep.2013.06.028
59. Chang DK, Cheng SF. 1996. On the importance of van der Waals interaction in the groove binding of DNA with ligands: restrained molecular dynamics study. Int J Biol Macromol 19:279-285. https://doi.org/10.1016/S0141-8130(96)01138-5
60. Sauers RR. 1995. An analysis of van der Waals attractive forces in DNA-minor groove binding. Bioorg Med Chem Lett 5:2573-2576. https://doi.org/10.1016/0960-894X(95)00438-Y
61. Hatcher EL, Wang C, Lefkowitz EJ. 2015. Genome variability and gene content in chordopoxviruses: dependence on microsatellites. Viruses 7:2126-2146. https://doi.org/10.3390/v7042126
62. Flatt JW, Greber UF. 2015. Misdelivery at the nuclear pore complex-stopping a virus dead in its tracks. Cells 4:277-296. https://doi.org/10.3390/cells4030277
63. Kobiler O, Drayman N, Butin-Israeli V, Oppenheim A. 2012. Virus strategies for passing the nuclear envelope barrier. Nucleus 3:526-539. https://doi.org/10.4161/nucl.21979
64. Puntener D, Greber UF. 2009. DNA-tumor virus entry-from plasma membrane to the nucleus. Semin Cell Dev Biol 20:631-642
65. Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 46: 1329-1335. https://doi.org/10.1128/AAC.46.5.1329-1335.2002
66. Moss B. 2013. Poxviridae, p 2129-2159. In Fields BN, Knipe DM, Howley PM, Cohen IJ, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 6th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA
67. Sekiguchi J, Shuman S. 1997. Mutational analysis of vaccinia virus topoisomerase identifies residues involved in DNA binding. Nucleic Acids Res 25:3649-3656. https://doi.org/10.1093/nar/25.18.3649
68. Mutsafi Y, Fridmann-Sirkis Y, Milrot E, Hevroni L, Minsky A. 2014. Infection cycles of large DNA viruses: emerging themes and underlying questions. Virology 466-467:3-14. https://doi.org/10.1016/j.virol.2014.05.037
69. Patel SR, Kvols LK, Rubin J, O'Connell MJ, Edmonson JH, Ames MM, Kovach JS. 1991. Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest New Drugs 9:53-57. https://doi.org/10.1007/BF00194545
70. Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER. 2007. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 51:4118-4124. https://doi.org/10.1128/AAC.00762-07
71. Mercer J, Helenius A. 2008. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320:531-535. https://doi.org/10.1126/science.1155164
72. Mercer J, Knebel S, Schmidt FI, Crouse J, Burkard C, Helenius A. 2010. Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc Natl Acad Sci U S A 107:9346-9351. https://doi.org/10.1073/ pnas.1004618107
73. Mercer J, Traktman P. 2003. Investigation of structural and functional motifs within the vaccinia virus A14 phosphoprotein, an essential component of the virion membrane. J Virol 77:8857-8871. https://doi.org/ 10.1128/JVI.77.16.8857-8871.2003